SAB Biotherapeutics, Inc. (SABS)


Stock Price Forecast

April 22, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading SAB Biotherapeutics, Inc. chart...

About the Company

We do not have any company description for SAB Biotherapeutics, Inc. at the moment.

Exchange

Nasdaq

$18M

Total Revenue

81

Employees

$41M

Market Capitalization

-8.52

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SABS News

SAB Biotherapeutics (SABS) Price Target Decreased by 10.00% to 18.36

6d ago, source: Fintel on MSN

The average one-year price target for SAB Biotherapeutics (NasdaqCM:SABS) has been revised to 18.36 / share. This is an ...

SAB Biotherapeutics Provides SAB-142 Trial Update

7d ago, source:

SAB-142 is a human alternative to rabbit anti-thymocyte globulin (ATG). SAB-142’s mechanism of action is analogous to that of rabbit ATG, which has been clinically validated in multiple clinical ...

SAB Biotherapeutics to Present at INNODIA Annual Meeting

15d ago, source:

MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage ...

SAB Biotherapeutics Inc SABS

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SAB Leaps On Completing Latest Cohort

7d ago, source:

Peloton Drops Free Membership Option <li /> ARKO Arm Trumpets New Location <li /> Ocean Power Technology Loses Ground on News ...

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

25d ago, source: Yahoo Finance

2024 (GlobeNewswire)—SAB Biotherapeutics, Inc. (Nasdaq:SABS), (“SAB” or “the company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing ...

SAB Biotherapeutics Inc. Wt

26d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

SAB Biotherapeutics to Present at INNODIA Annual Meeting

15d ago, source: Business Insider

MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical ...

SAB Biotherapeutics Inc. Wt

26d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...